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Abstract: 
This chapter reviews the current technologies for monitoring and intervention of diabetes. Especially 
various blood glucose concentration estimation, online signal monitoring and adaptive control 
mechanisms are discussed. Recent research has proposed many control engineering approaches for 
Type 1 diabetes and many algorithms of artificial pancreas have been proposed. This book chapter 
reviews the current state of the art and industrial standards on diabetes monitoring and control.  
1. Measurements, Model Estimation and Control of Diabetes 
Diabetes control is inherently an interdisciplinary field of study. Almost 50 years of research has been 
done on this which has proposed many models and closed control strategies to develop artificial 
pancreas. Diabetes is a metabolic disorder characterized by chronic hyperglacemia leading to 
microvascular and macrovascular complications. Diabetes can be divided in two categories – type 1 
and type 2, although their pathogenesis is different. Type 1 diabetes is caused due to immune-mediated 
destruction of the beta-cells in the site of insulin secretion and production. This is not related to obesity 
but it can cause other cardiac complications. Type 1 diabetes is usually treated by insulin therapy to 
control hyperglycemia and for sustain life. Whereas in type 2 diabetes, the insulin secretion is 
inadequate which results in gyperglycemia. Usually the type 2 diabetes is related to increasing age 
(usually after 40), excess caloric intake, less physical activity, obesity which are play a big role in its 
development. It also causes other cardiovascular risks like dyslipidemia and hypertension. It has been 
estimated that almost 90% of the world diabetes population is of type 2 and 5-10% is of type 1. Over 
the years, diabetes leads to many other complications like diabetic retinopathy (leading to blindness), 
diabetic neuropathy (leading to limb loss), kidney failure, heart disease and stroke with double risk of 
dying.  
The world health organization (WHO) has estimated that more than 180 million people in the world 
have diabetes which is likely to be doubled by 2020 [1]. Diabetes is the fifth highest case of death after 
communicable diseases, cardiovascular diseases, cancer and injury and also is a primary cause of death 
in low and middle income countries. Due to high complexity of this disease, studies of many disciplines 
are needed e.g. physiology and pathophysiology, dugs, artificial pancreas, transplantation, patient 
management, healthcare, systems biology.    
The glucose insulin control system in the body is regulated by a complex neuro-hormonal control 
system. It is done by insulin which is the primary regulator of glucose homeostasis that promotes 
glucose utilization and inhibits glucose production for stored resources in the body. Counter-regulatory 
hormones like glucagon, epinephrine, cortisol, and growth hormone which work in different scales 
defends the body from life threatening hypoglycaemia. The insulin control and hypoglycaemia counter-
regulation are balanced by neuro-modulation. Glucose in the body is produced by the liver and utilized 
in both insulin dependent (which includes central nervous system, red blood cells) and insulin 
independent tissues (muscle and adipose tissues). Insulin is secreted by the beta-cells in the pancreas, 
and then reaches the system circulation after liver degradation and finally cleared by the kidney. The 
glucose and insulin systems interact by feedback control signals e.g. after a meal when the glucose 
perturbation occurs, the beta-cells secret more insulin after sensing the high plasma glucose 
concentration. This promotes glucose utilization and inhibits the glucose production to balance the 
plasma glucose which are known as the insulin sensitivity and beta-cell responsivity both of which are 
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progressively deteriorated in type 2 diabetes. In type 1 diabetes, the beta cells becomes silent in response 
to the glucose perturbation and therefore, insulin must be provided exogenously into the patient’s body 
to compensate for the hyperglycemia. However, often insulin treatment is risky and may lead to severe 
hypoglycaemia. Therefore, for type 1 diabetic patients it is challenge to maintain reduce hyper-glycemia 
without increasing the risk of hypo-glycemia. Blood glucose level is the measured quantity in such 
optimization and several control models have been developed to assist diabetes control. The following 
section reviews few models commonly used in diabetes control. 
2. Minimal Models                 
Minimal models describes the key functionality, rather than describes the detailed substrate/hormone 
interactions. In addition minimal models on contrary are much simpler and for large detailed models, it 
is usually difficult to estimate all model parameters from in-vivo dynamic data. The desirable features 
for a minimal model include: 
 Physiologically motivated 
 Parameter estimation possible with good precision with a single dynamic response of the system 
 The model parameters should vary within physiologically plausible ranges 
 The whole system dynamics can be described with minimum number of parameters. 
The glucose system is divided in many parts of a compartmental model [1] viz. 
 Steady state insulin action 
 Non-steady state insulin action 
 Dynamic perturbation 
 Dynamic perturbation with tracer 
The response of plasma glucose and insulin to an oral or intravenous administration of glucose is given 
by the following system of ordinary differential equations (ODEs): 
 
 
     
 




a G t a I t J t
dt
dI t
a G t a I t
dt
   
 
  (1) 
where, the system parameters are given as: 
G: plasma glucose, 
I: plasma insulin, 
J: glucose input either as an intravenous injection or the absorption rate of glucose during a meal or an 
oral glucose tolerance test. 
The minimal model assumes that glucose kinetics can be described by one compartment and the remote 
insulin controls both the net hepatic glucose balance and peripheral glucose disposal: 
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where, the parameters are given by: 
Q: plasma glucose mass, 
bQ : basal value of the plasma glucose mass, 
I: plasma insulin concentration, 
bI : basal value of the plasma insulin concentration, 
D: glucose dose, 
V: glucose distribution volume, 
k2, k3 are the rate parameters.  
The net hepatic glucose balance (NHGB) depends upon plasma glucose and remote insulin ( I  ) as: 
         0 5 6NHGB , NHGBQ t I t k k I t Q t         ,  (3) 
where, dR  is the rate of glucose disappearance from the peripheral tissues and given by: 
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This nonlinear model is usually reparametrized in order to be uniquely identifiable as: 
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with the following relations: 
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The meaning of the parameters are:  
X: insulin action, 
p1: fractional (i.e. per unit distribution volume) glucose effectiveness, 
p2: rate constant of the remote insulin compartment where the insulin action emanates from, 
p3: scale factor which governs the amplitude of insulin action. 











IS is a steady-state measure which means it does not account for how fast or slow the insulin 
action takes place.  
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with  1 2, , , N     the parameter vector describing Ra. 
In the dynamic perturbation with tracer category, another important quantity is the endogenous glucose 
production (EGP) responsible for negligible or negative action of insulin on the liver and is given by: 
          , 0L Lb b bEGP t EGP GE G t G X t G t EGP EGP            (9) 
where, the parameters are given as: 
bEGP : basal endogenous glucose production, 
LGE : liver glucose effectiveness, 
G: glucose concentration and bG  being its basal value, 
LX  is the liver insulin action or the deviation from insulin. 
This follows the following dynamical system: 
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where, p2: rate constant describing the dynamic action of insulin action on glucose production, 
3
Lp : scale factor governing amplitude of hepatic insulin action. 
An improved model has been suggested in [1] as: 
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where LX  can be described by the system of ODEs: 
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Lp : rate constant describing dynamics of insulin action on glucose production, 
3
Lp : scale factor governing amplitude of hepatic insulin action, 
GRk : parameter governing magnitude of glucose derivative control.  
The endogenous glucose production can be calculated by using the endogenous glucose concentration 
( endG ) which indicates the compartment of total glucose concentration measured in plasma due to 
glucose production. The quantity endG is related to the endogenous glucose production EGP by the 
integral equation: 
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where,  ,h t  is the time-varying impulse response of glucose system given by tracer minimal model 
and bG  is basal glucose.  
The whole body to tissue model usually employs tracer elements and is described the following ODEs: 
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and  
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where, the parameters are given as: 
pC : Fluorodeoxyglucose (FDG) plasma arterial concentration, 
cC : Extra-cellular concentration of FDG normalized to tissue volume, 
eC : FDG tissue concentration, 
C: Total 18F activity concentration in the region of interest, 
K1 [ml/ml/min] and k2 [min-1] are the exchange between plasma and extracellular space, 
k3 [min-1] and k4 [min-1] are the rate of transport in and out of the cell, 
k5 [min-1] is the rate of phosphorylation, 
bV : fractional blood volume in the region of interest, 
bC : whole blood tracer concentration. 
From these models one can calculate the fractional uptake of the FDG, K [ml/ml/min] as: 
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2 4 2 5 3 5
K k k
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  (17) 
6 
 
More details of this model can be found in [1]. 
For an insulin system, firstly an insulin kinetics model in steady state and insulin secretion can be 
investigated. The C-peptide concentration measurements (C) are linear in a wide range of concentration 
and related to the basal pancreatic secretion by the following convolution integral: 
      
0
t
C t h t SR d        (18) 
where, h is the impulse response function of this system. 
As described before, during IVGTT, the basal insulin secretion model is given by the pancreatic 
secretion rate (SR) as: 
    SR t m F t    (19) 
with F as the ready releasable insulin given by the ODE: 
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with F0 the amount of insulin released immediately after the glucose stimulus and  ,Y G t  is the 
provision of new insulin which depends on the glucose level: 
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3. Maximal Models  
Compared to the minimal models as described above, the maximal models are more detailed or fine-
grained, nonlinear, higher order and with large number of parameters to estimate. Usually such models 
are not possible to estimate without running large experimental investigations. However, such models 
have been widely used for simulation purpose to check model validity. A healthy state simulator has 
been described in [1] on 204 nondiabetic subjects with simulation models of plasma glucose, plasma 
insulin, endogenous glucose production, glucose rate of appearance, glucose utilization, insulin 
secretion etc. Maximal models have also been used for prediabetes and type 2 diabetes simulator, type 
1 diabetes simulator with unit process models and forcing functions for the liver, gastro-intestinal tract, 
muscle and adipose tissue, beta cell. In-silico subject simulation has been reported in [1] with a feedback 
controller and simulated insulin pump for type 1 diabetes. For the insulin secretion the following mass 
balance equations are used for the intermediate pool (I): 
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where, M is the mobilization flux and r is the rate of reinternalization. 
The readily releasable pool (RRB) can be described by the time varying density function  ,h g t  that 
indicates the amount of insulin in the RRP in beta-cells with a threshold between g and (g + dg). The 
granules are primed with rate p and they are assumed to loose the capacity with rate p . It is also 








p I t j g p h g t f h g t G g
dt
           .  (23) 
7 
 
Here,  G g  is the Heaviside step function which takes the value of unity for G g and zero 
otherwise. Also, I is total intermediate pool, the primary flux p I  distributes among cells with 
threshold g, described the time constant function  j g . 
4. Diabetes Monitoring Signals and Controls 
Various signal processing techniques have been historically used since 1970s during in-hospital 
monitoring of blood glucose concentration and other substances like insulin, C-peptide, glucagon etc. 
New continuous glucose monitoring (CGM) systems have emerged recently that are capable of 
monitoring glucose concentration as frequently as every 5 minutes. These CGM monitoring devices are 
minimally invasive, portable, measuring glucose subcutaneously and assessing blood glucose 
concentration indirectly though interstitial fluid sampling. Although the measurement accuracy are not 
fully solved yet but this technology shows high potential for real-time prevention and treatment of hypo- 
and hyper-glycemia. Amongst various signal processing methods, glucose-insulin oscillations, peak 
detection and spectral/correlation analysis, hormone pulsatility and use of approximate entropy are 
notable. Other challenges of continuous glucose monitoring with time series data include CGM sensor 
calibration, CGM vs. blood glucose measurement, filtering, prediction, hypoglycaemia vs. 
hyperglycemia alert etc.  
Several architectures have been proposed for glucose control. This includes safety algorithms and real-
time control. In various real-time control schemes, the feedback and feedforward control, autoregressive 
moving average exogenous (ARMAX) and nonlinear ARMAX system identification, proportional 
integral derivative (PID) control, model predictive control (MPC) with quadratic cost and constraints 
on the manipulated variables (insulin pump), real-time detection and estimation using Kalman filter are 
notable [1]. For tuning the control loops various strategies have been adopted e.g. control variability 
grid analysis, robustness vs. personalization of the controller parameters, run to run control and 
behavioural analysis etc. More in-depth models, signals and control strategies for diabetes are discussed 
in [1] and the large number of references therein.           
Recently, Turksoy et al. [2] introduced a multi-module multivariable adaptive control strategy for 
artificial pancreas for type 1 diabetes. The artificial pancreas collects information from many sensors, 
computes the optimal insulin amount to be infused and the then manipulates the infusion rate of the 
pump. A recursive model of glucose concentration dynamics is first estimated using the ARMAX 
method of system identification. The controller takes various inputs e.g. 
 Glucose and activity feedback 
 Hypoglycemia detection and carbohydrates suggestion 
 Meal detection and hyperglycemia prevention 
 Exercise classification 
 Fault detection and diagnosis. 
Using these inputs the multivariable adaptive controller drives the insulin infusion pump for the patient. 
The measurements in this scheme are used as – continuous glucose monitoring sensor and wearable 
biometric sensors. The study in [2] also concluded with clinical experiments that the multivariable 
approach provides better results than the single variable version using only CGM measurement.  
Meal detection has further been researched in [3] for nine patients with type 1 diabetes over 27 different 
main meals. The multivariable adaptive artificial pancreas system includes a minimal model similar to 
equation (1), followed by unscented Kalman filter for state estimation of the nonlinear system. The 
CGM measurements are used for nine subjects during breakfast, lunch, dinner to validate the algorithm. 
A similar analogue PID based glucose control algorithm was implemented in [4] using a β-cell model 
and comprising of an ODE and the sigmoid function, known as the Hill equation. For type 1 diabetes 
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control using artificial pancreas, PID and sliding mode reference conditioning based safety auxiliary 
feedback control has been implemented in [5] with enhanced robustness and fault-tolerance properties. 
A model predictive iterative learning control (MPILC) scheme has been proposed in Wang et al. [6] for 
artificial pancreatic β-cells in type 1 diabetes. This involves a virtual patient which uses an 
autoregressive exogenous (ARX) model. Robustness of the MPC and ILC on repetitive and non-
repetitive diets, robustness to subject variations, set-point updating have also been investigated.  
For type 1 diabetes patients an improved overnight safety scheme has been proposed in Facchinetti et 
al. [7] for online failure detection of the glucose sensor and insulin pump system. There are two cases 
considered viz. CGM sensor failure and continuous subcutaneous insulin infusion (CSII) pump failure. 
The failure detection employ a Kalman predictor and online prediction and alert module. The method 
was validated on in-silico data of 100 virtual subjects and also real type 1 diabetes mellitus (T1DM) 
data. Robustness of the failure detection monitoring system against noise and domain of validity has 
also been investigated on these two databanks.    
In the field of closed loop control of diabetes, the MPC has been found to have wide applicability over 
conventional therapy in the development of artificial pancreas with various modules e.g. data 
handling/filtering, state estimation/update, closed-loop control algorithm, safety supervision algorithm, 
actuation, data-logging and outcome measures etc. [8]. For modular control the two important issues 
are – design flexibility, incremental testing, regulatory approval and deployment. The safety supervision 
algorithm has various elements like insulin request classifier, correction filter, other elements like 
hypoglycaemia indicators etc. This system is based on a linear MPC which has linearized model of the 
nonlinear insulin-glucose dynamics. Also, the MPC works on the difference between the CGM signal 
and the patient’s nominal blood glucose profile with improved individualization capability and has been 
validated on in-silico experiments.      
5. Non-invasive Diabetes Monitoring 
Recently, more works are devoted on non-invasive monitoring of diabetes. As an example, Pai et al. 
[9] used a cloud computing platform to implement a photoacoustic spectroscopy system with detailed 
calculation of the signal to noise ratio (SNR). In the calibration and testing phase, several well-known 
signal processing operations like pre-processing, feature extraction (e.g. positive/negative peaks, 
max/min peak, peak to peak amplitudes), followed by in-vitro and in-vivo testing, glucose estimation 
using polynomial kernels. The estimation performances were compared with respect to three accuracy 
measures: root mean square error (RMSE), mean absolute difference (MAD), mean absolute relative 
difference (MARD) which results in a kernel based calibration model for continuous non-invasive 
glucose monitoring using photoacoustic measurements. The algorithm has been deployed in mobile 
cloud computing platform with internet of things (IoT) devices, internet gateway, cloud services with 
dataflow pipelines like data processing, data analytics, data storage, application control etc. the 
embedded back-end implementation was tested against power consumption, security, in-vitro testing, 
system stability, safety, in-vivo testing etc.        
Much of the future research in this domain are expected to have few key functionalities: unobtrusive 
sensing, modelling the onset and progress of diabetes mellitus and user-centred approach [10].  
Zarkogianni et al. [10] reviewed various emerging technologies for the management of diabetes 
mellitus. Amongst the commercially available devices only two uses non-invasive methods like Raman 
spectroscopy (HG1-c by C8 Medisensors) and thermal ultrasound and electromagnetic (GlucoTrack by 
Integrity Applications Ltd.). These devices has been benchmarked against other invasive devices by 
Dexcom, Medtronic and Abbott with detailed comparison of the sensor lifetime, sensor warm up time, 
frequency of calibration, frequency of recording, accuracy etc. Several artificial intelligence (AI) 
models for type 2 diabetes risk prediction and early diagnosis has been reviewed in [10] e.g. fuzzy 
neural networks (FNN), adaptive neuro-fuzzy inference system (ANFIS), support vector machine 
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(SVM), linear discriminant analysis (LDA), adaptive network based fuzzy inference system and mixture 
of experts (ME) and their performances are compared using classification accuracy, sensitivity, 
specificity etc. For long-term risk modelling several statistical models e.g. cox regression, Tobit 
survival regression, Cox proportional hazard model and fractional polynomials, univariate and 
multivariate logistic regression, survival analysis, Weibull proportional hazard regression, Markov 
model etc. have been used for different size of cohorts (55, >1000, >5000, >1.2 million etc.). Moreover, 
several glucose prediction models are compared in [10] based on AI and autoregressive models. Long 
term implanted sensor/telemetry systems are studied in [11] for glucose monitoring for patients with 
diabetes. Raman spectra of blood has also been used for glucose monitoring devices in [12].  
6. Recent Research Trends in Diabetes Monitoring and Control  
Diabetes monitoring and control is emerging as a prominent research discipline. In the Scopus search 
some patterns were retrieved for the first 2000 highest cited papers on this topic. The word-clouds in 
Figure 1 shows that in the papers titles, few frequently used words are: diabetes, glucose, type1 and 2, 
insulin, monitoring along with some relatively less used words like cardiovascular, glycemic, close-
loop, management, self-monitoring, pump etc. These word frequencies show the relative research 
efforts and different sub-areas in this field which are actively growing. Figure 2 also shows a bar chart 
of type of recently published works which shows there were many more journal research articles than 
review articles, followed by conference papers, short survey and letters.  
 
Figure 1: Word-clouds of the titles of recent diabetes monitoring research papers. Datasource: Scopus. 
Similar to exploring the article titles, next Figure 3 shows the indexed and author’s keywords in the top 
2000 papers in this active research area. As opposed to the title based text analysis, often the keyword 
based analysis is capable of capturing finer technical details or an emphasis of fewer most popular 
technologies. In both the word-clouds, apart from diabetes, the most frequent words were glucose, 
insulin, blood, monitoring, continuous, control etc. which shows the finer details of the technologies 
gradually increasing over the years. While exploring the citation patterns in this research field in Figure 
4, it is clear that the citations of the papers on diabetes monitoring has rather a drooping characteristics, 
at least for the upper quartile. The gradual decrease in the median citation from year 2000 almost follows 
an exponential trend, because the citation dynamics is usually a cumulative phenomenon and as such 
recent technological advancements take years to get assimilated in clinical practice. Also there are more 
outliers in the papers between the years 2001-2013 as shown in Figure 4 which indicate there are few 
highly impactful papers, compared to the citation of average papers published in the recent years. Next 
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we, explore the source titles of the top 2000 papers on this topic as shown in Figure 5. It is evident that 
most of the impactful papers were published in the journals like Diabetes Care (American Diabetes 
Association), Diabetes Technology and Therapeutics (Liberto Pub.), Journal of Diabetes Science and 
Technology (Sage), Diabetic Medicines (Wiley), Diabetologia, Diabetes (American Diabetes 
Association), The Lancet, IEEE Transactions on Biomedical Engineering etc. A more focussed study 
on mobile health technologies for diabetes mellitus ranging the years 2011-2017 and using 3 databases 
– ScienceDirect, SpringerLink and IEEEXplore have been reported in [13].  
 
Figure 2: Type of recent papers on diabetes monitoring system. Datasource: Scopus. 
 
Figure 3: Indexed and author’s keywords for recent papers on diabetes monitoring system. Datasource: 
Scopus.  
With the advent of 5G and smart technologies several personalized options has opened to analyse big 
healthcare data on clouds [14]. The 5 goals of such technology using 5G are – cost-effectiveness, 
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comfortability, personalization, sustainability, smartness. The 5G-smart diabetes architecture in [14] 
has three layers – sensing layer, personalized diagnosis layer, data sharing layer. The performance was 
validated using machine learning algorithms like decision tree, artificial neural network (ANN), SVM, 
ensemble etc. which suggests on prevention and treatment of diabetes using recommendations like diet, 
sport, data sharing in a social network etc.   
 
Figure 4:  Year-wise citations of recent papers on diabetes monitoring system. Datasource: Scopus. 
 
Figure 5: Source titles for recent works on diabetes monitoring system. Datasource: Scopus. 
7. Conclusion 
This book chapter reviews the recent trends in diabetes monitoring using the top 2000 cited articles and 
report text analytics results on past research activities and emerging trends in this domain. It also 
reviews various diabetes monitoring and control models available in the literature which are primarily 
divide din two categories – minimal and maximal models. Although the citation trends suggest that 
fundamental research in this domain is nearly to a saturated level. However, there are many 
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commercialization activities and patents issued recently on this topic [15], which shows a new 
opportunity to grow new industries in this domain which needs a good and affordable business model 
particularly for low and medium income countries of the developing world where diabetes is emerging 
almost in the scale of a large epidemic. 
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